COGT

Cogent Biosciences, Inc. [COGT] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

COGT Stock Summary

Top 10 Correlated Stocks

COGT


In the News

11:23 10 Dec 2023 COGT

3 Lost Formula Stocks to Consider for the 2nd Half of 2023

Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023.

08:00 10 Dec 2023 COGT

Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)

WALTHAM, Mass. and BOULDER, Colo.

08:00 10 Dec 2023 COGT

Cogent Biosciences Announces Participation at Upcoming Investor Conferences

WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the following upcoming virtual investor conferences:

10:55 10 Dec 2023 COGT

These Are the Top 10 Holdings of David Kim

David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 2012).

02:17 10 Dec 2023 COGT

Cogent Biosciences: Bezuclastinib's Potential In Treating Gastrointestinal Stromal Tumors

Cogent Biosciences is a biotechnology company focused on developing solutions for complex medical conditions, with a particular focus on Gastrointestinal Stromal Tumors. Bezuclastinib is a promising tyrosine kinase inhibitor that targets KIT exon 17/18 mutations, commonly found in patients with advanced and/or treatment-resistant GIST.

07:02 10 Dec 2023 COGT

Cogent Biosciences: Multiple Inflection Points For FY23, Hold For Now

Cogent Biosciences, Inc. is building momentum around its bezuclastinib compound. FY22 saw a number of positive advancements of the company's pipeline.

08:00 10 Dec 2023 COGT

Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis

WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held on Monday, December 12, 2022 at 8:00 a.m. ET (7:00 a.m. CT) to discuss updated clinical data from its on-going Phase 2 APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis being presented at the 64th American Society of Hematology (ASH) Annual Meeting.

01:16 10 Dec 2023 COGT

Cogent Biosciences: What's Ahead

Today, we put Cogent Biosciences, Inc. in the spotlight for the first time in nearly two years. Cogent stock has roughly tripled since positive trial data came out in June, and the company has addressed its current funding needs.

11:35 10 Dec 2023 COGT

Wall Street Analysts See a 66% Upside in Cogent Biosciences, Inc. (COGT): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 66.1% in Cogent Biosciences, Inc. (COGT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

12:02 10 Dec 2023 COGT

Cogent (COGT) Surges on Robust Data from Mastocytosis Study

Cogent's (COGT) bezuclastinib achieves robust effectiveness in patients with advanced systemic mastocytosis with a favorable safety and tolerability profile. Stock surges more than 58% on Jun 10.

COGT Financial details

Company Rating
Neutral
Market Cap
744.11M
Income
-168.89M
Revenue
0
Book val./share
3.52
Cash/share
3.24
Dividend
-
Dividend %
-
Employees
138
Optionable
No
Shortable
Yes
Earnings
02 Nov 2023
P/E
-4.41
Forward P/E
-4.19
PEG
-1.27
P/S
-
P/B
2.46
P/C
2.67
P/FCF
-7.07
Quick Ratio
8.04
Current Ratio
9.01
Debt / Equity
0.06
LT Debt / Equity
0.06
-
-
EPS (TTM)
-2.21
EPS next Y
-2.06
EPS next Q
-0.56
EPS this Y
37.8%
EPS next Y
-6.79%
EPS next 5Y
-10.67%
EPS last 5Y
-16.45%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
8.47%
-
-
-
-
SMA20
1.51%
SMA50
-19.1%
SMA100
-34.97%
Inst Own
76.38%
Inst Trans
0.61%
ROA
-48%
ROE
-60%
ROC
-0.6%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
86.12M
Shs Float
69.02M
-
-
-
-
Target Price
20.33
52W Range
6.43-15.68
52W High
-42.4%
52W Low
+44%
RSI
58.95
Rel Volume
1.51
Avg Volume
952.71K
Volume
1.43M
Perf Week
15.97%
Perf Month
-1.93%
Perf Quarter
-29.53%
Perf Half Y
-26.15%
-
-
-
-
Beta
-0.201
-
-
Volatility
0.36%, 0.69%
Prev Close
-1.48%
Price
8.64
Change
-0.23%

COGT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.562.950.7100
Net income per share
-5.55-3.97-6-1.64-2.26
Operating cash flow per share
-5.22-5.45-3.24-1.34-2.02
Free cash flow per share
-5.31-5.45-3.24-1.38-2.14
Cash per share
12.634.9121.865.014.41
Book value per share
9.684.1721.184.894.35
Tangible book value per share
9.684.1721.184.894.35
Share holders equity per share
9.684.1721.184.894.35
Interest debt per share
0.610.790.470.070.4
Market cap
109.54M21.95M124.44M375.85M679.03M
Enterprise value
53.87M-9.45M-112.54M159.33M558.79M
P/E ratio
-3.17-0.72-1.87-5.23-5.12
Price to sales ratio
11.250.9815.8100
POCF ratio
-3.37-0.53-3.47-6.4-5.72
PFCF ratio
-3.32-0.53-3.47-6.21-5.41
P/B Ratio
1.820.690.531.752.66
PTB ratio
1.820.690.531.752.66
EV to sales
5.53-0.42-14.300
Enterprise value over EBITDA
-1.550.291.25-2.11-3.78
EV to operating cash flow
-1.660.233.14-2.71-4.71
EV to free cash flow
-1.630.233.14-2.63-4.45
Earnings yield
-0.32-1.38-0.53-0.19-0.2
Free cash flow yield
-0.3-1.89-0.29-0.16-0.18
Debt to equity
0.060.190.020.010.08
Debt to assets
0.040.120.020.010.07
Net debt to EBITDA
1.610.982.642.870.81
Current ratio
3.253.0618.713.049.87
Interest coverage
0000-37.06
Income quality
0.941.30.480.810.85
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.770.492.2100
Research and developement to revenue
3.931.949.2300
Intangibles to total assets
00000
Capex to operating cash flow
0.02000.030.06
Capex to revenue
-0.060000
Capex to depreciation
-0.42-0.030-11.69-1.17
Stock based compensation to revenue
0.320.140.7600
Graham number
34.7619.353.4513.4314.87
ROIC
-0.59-0.7-0.3-0.34-0.47
Return on tangible assets
-0.4-0.61-0.26-0.31-0.44
Graham Net
8.72.7920.394.613.65
Working capital
56.06M27.34M231.82M205.56M238.12M
Tangible asset value
60.23M31.76M234.67M214.18M255.74M
Net current asset value
55.31M22.93M228.66M204.73M219.89M
Invested capital
0.060.190.020.010.08
Average receivables
1.25M1.83M1000K00
Average payables
1.43M2.35M1.96M2.11M4.66M
Average inventory
37.5K0000
Days sales outstanding
62.5532.45000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
5.8411.25000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.57-0.95-0.28-0.34-0.52
Capex per share
-0.0900-0.04-0.12

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.48-0.5-0.48-0.59-0.64
Operating cash flow per share
-0.49-0.42-0.56-0.430
Free cash flow per share
-0.54-0.45-0.57-0.450
Cash per share
4.163.683.114.413.24
Book value per share
4.173.633.164.663.52
Tangible book value per share
4.173.633.164.663.52
Share holders equity per share
4.173.633.164.663.52
Interest debt per share
0.310.310.210.260.22
Market cap
1.04B814.86M763.23M885.08M840.12M
Enterprise value
917.59M694.62M621.99M690.12M772.48M
P/E ratio
-7.79-5.74-5.62-5.02-3.79
Price to sales ratio
00000
POCF ratio
-30.14-27.71-19.31-27.60
PFCF ratio
-27.5-25.97-18.79-26.560
P/B Ratio
3.583.193.412.542.77
PTB ratio
3.583.193.412.542.77
EV to sales
00000
Enterprise value over EBITDA
-27.71-15.88-14.63-14.66-12.97
EV to operating cash flow
-26.64-23.62-15.74-21.520
EV to free cash flow
-24.31-22.14-15.31-20.710
Earnings yield
-0.03-0.04-0.04-0.05-0.07
Free cash flow yield
-0.04-0.04-0.05-0.040
Debt to equity
0.070.080.090.060.06
Debt to assets
0.060.070.070.050.05
Net debt to EBITDA
3.642.753.324.141.14
Current ratio
12.599.8710.7112.999.01
Interest coverage
-24.55-20.739.300
Income quality
0.980.741.020.730
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.10.070.030.040
Capex to revenue
00000
Capex to depreciation
-0.89-2.1-1.53-1.030
Stock based compensation to revenue
00000
Graham number
6.76.415.847.867.13
ROIC
-0.11-0.13-0.14-0.11-0.17
Return on tangible assets
-0.1-0.12-0.13-0.11-0.16
Graham Net
3.563.042.553.822.63
Working capital
272.87M238.12M205.15M308.76M278.12M
Tangible asset value
289.94M255.74M223.56M348.43M302.9M
Net current asset value
254.8M219.89M186.64M290.58M260.29M
Invested capital
0.070.080.090.060.06
Average receivables
00000
Average payables
3.79M4.97M5.01M5.67M8.51M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.11-0.14-0.15-0.13-0.18
Capex per share
-0.05-0.03-0.02-0.020

COGT Frequently Asked Questions

What is Cogent Biosciences, Inc. stock symbol ?

Cogent Biosciences, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol COGT

Is Cogent Biosciences, Inc. buy or a sell ?

3 stock analysts have 3 predictions with a medium analyst target price of $20.33. The lowest prediction is $15 and the highest is $24

What is COGT stock prediction ?

What is Cogent Biosciences, Inc. stock quote today ?

Cogent Biosciences, Inc. stock price is $8.64 today.

Is Cogent Biosciences, Inc. stock public?

Yes, Cogent Biosciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated Stocks
Similar Market Cap